ArticlePloS one2012
The antimicrobial peptide cathelicidin protects mice from Escherichia coli O157:H7-mediated disease.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 88 citations in OpenAlex.
- Inhibitory Effects of Oxysterlina 3, Satanin 1, and Curvicin Cecropins on the Growth and stx2 Gene Expression of Shiga Toxin-Producing Escherichia coli (STEC).Current microbiology · 2026Article
- α-Helical Peptides Encoded in Collagen Exhibit Antimicrobial Activity with Low Cytotoxicity.Journal of natural products · 2026Article
- Cellular signaling pathway of Shiga toxin-induced ATP release.Frontiers in cellular and infection microbiology · 2026Article
- Cathelicidin regulates goblet cell mucus secretion and mucus-associated proteins inGut microbes · 2025Article
- Post-burn Lung Inflammation Is Associated With Induction of Pulmonary Cathelicidin-related Antimicrobial Peptide and S100a8 in Mice.Journal of burn care & research : official publication of the American Burn Association · 2025Article
- Secretory leukocyte protease inhibitor protects against severe urinary tract infection in mice.mBio · 2024Article
- Gut-Antimicrobial Peptides: Synergistic Co-Evolution with Antibiotics to Combat Multi-Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Secretory Leukocyte Protease Inhibitor Protects Against Severe Urinary Tract Infection in Mice.bioRxiv : the preprint server for biology · 2023Article
- Expression of antimicrobial host defence peptides in the central nervous system during health and disease.Discovery immunology · 2022Review
- Synergistic Antimicrobial Effect of Antimicrobial Peptides CATH-1, CATH-3, and PMAP-36 With Erythromycin Against Bacterial Pathogens.Frontiers in microbiology · 2022Article
- Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8The journal of pathology. Clinical research · 2021Article
- Growth Performance, Biochemical Blood Indices, and Large Intestine Physiology of Rats Fed Diets with Alfalfa Protein-Xanthophyll Concentrate.Animals : an open access journal from MDPI · 2021Article
- The microbiome and host mucosal interactions in urinary tract diseases.Mucosal immunology · 2021Review
- Distinct contributions of cathelin-related antimicrobial peptide (CRAMP) derived from epithelial cells and macrophages to colon mucosal homeostasis.The Journal of pathology · 2021Article
- The Antimicrobial Peptide Mastoparan X Protects Against EnterohemorrhagicFrontiers in microbiology · 2021Article
- Cathelicidin protects mice from Rhabdomyolysis-induced Acute Kidney Injury.International journal of medical sciences · 2021Article
- Interplay between gut microbiota and antimicrobial peptides.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2020Review
- Cathelicidins Mitigate Staphylococcus aureus Mastitis and Reduce Bacterial Invasion in Murine Mammary Epithelium.Infection and immunity · 2020Article
- Cathelicidin Mediates a Protective Role of Vitamin D in Ulcerative Colitis and Human Colonic Epithelial Cells.Inflammatory bowel diseases · 2020Article
- The Network of Colonic Host Defense Peptides as an Innate Immune Defense Against Enteropathogenic Bacteria.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the role of the antimicrobial peptide cathelicidin in Escherichia coli O157:H7 infection and subsequent renal damage. Mouse and human cathelicidin, CRAMP and LL-37, respectively, killed E. coli O157:H7 in vitro. Intestines from healthy wild-type (129/SvJ) and cathelicidin-knock-out (Camp(-/-)) mice were investigated, showing that cathelicidin-deficient mice had a thinner colonic mucus layer compared with wild-type mice. Wild-type (n = 11) and cathelicidin-knock-out (n = 11) mice were inoculated with E. coli O157:H7. Cathelicidin-deficient animals exhibited higher fecal counts of E. coli O157:H7 and bacteria penetrated the mucus forming attaching-and-effacing lesions to a much higher extent than in wild-type animals. Cathelicidin knock-out mice developed symptoms (9/11) as well as anemia, thrombocytopenia and extensive renal tubular damage while all cathelicidin-producing mice remained asymptomatic with normal laboratory findings. When injected with Shiga toxin intraperitoneally, both murine strains developed the same degree of renal tubular damage and clinical disease indicating that differences in sensitivity to infection between the murine strains were related to the initial intestinal response. In conclusion, cathelicidin substantially influenced the antimicrobial barrier in the mouse colon mucosa. Cathelicidin deficiency lead to increased susceptibility to E. coli O157:H7 infection and subsequent renal damage. Administration of cathelicidin or stimulation of endogenous production may prove to be novel treatments for E. coli O157:H7-induced hemolytic uremic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.